Welcome to our dedicated page for Mirum Pharmaceuticals SEC filings (Ticker: MIRM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Mirum Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Mirum Pharmaceuticals's regulatory disclosures and financial reporting.
Mirum Pharmaceuticals, Inc. (MIRM) reports a leadership transition in its medical organization. The board appointed Rob Myers, M.D. to succeed Joanne Quan, M.D. as Chief Medical Officer, effective when Dr. Myers begins employment, which is expected on September 21, 2026. Dr. Quan ceased serving as Chief Medical Officer on September 2, 2026, and her employment termination is expected on October 19, 2026, the defined “Separation Date.”
Mirum expects to enter into a Separation Agreement with Dr. Quan providing severance benefits under its Amended and Restated Severance Benefit Plan, subject to its terms. The compensation committee also approved a 12‑month post‑termination option exercise window for Dr. Quan’s vested options and payment of her 2026 annual target bonus at 100% achievement on the Separation Date, contingent on customary conditions.
Mirum Pharmaceuticals, Inc. (MIRM) reported that Jolanda Howe, its Senior Vice President and Global Controller, sold 658 shares of common stock on September 2, 2026 in a sale described as occurring in the open market or a private transaction at $100.00 per share.
After this sale, Howe held 616 shares of Mirum common stock directly. The transaction was carried out pursuant to a Rule 10b5-1 trading plan adopted by Howe on March 18, 2026, indicating it was pre-arranged.
Mirum Pharmaceuticals, Inc. (MIRM) reported that Chief Executive Officer Christopher Peetz exercised fully vested stock options for 30,000 shares of common stock on September 1, 2026 at an exercise price of $2.936 per share, receiving 30,000 shares of common stock. On the same date, he sold 8,312 shares at a weighted average price of $98.08 per share and 21,688 shares at a weighted average price of $98.91 per share under a Rule 10b5-1 trading plan adopted on March 2, 2026. Following the option exercise, he held 58,487 stock options directly and 187,500 shares of common stock indirectly through The Peetz Family Trust.
Mirum Pharmaceuticals, Inc. (MIRM) is the issuer in a Rule 144 notice covering proposed sales of its common stock for the account of officer Jolanda Marie Howe. The planned sale involves 658 shares of common stock through a broker, Morgan Stanley Smith Barney LLC Executive Financial Services, with a stated dollar amount of $65,800.00 as of September 2, 2026.
The shares to be sold are identified as restricted stock acquired from the issuer on January 23, 2026. The notice also lists prior sales by Jolanda Marie Howe over the preceding three months, including 40,000 shares for $4,000,000.00 on August 18, 2026 and several smaller transactions in June, July, and early August 2026.
Mirum Pharmaceuticals, Inc. (MIRM) received a Rule 144 notice from stockholder Christopher Peetz covering a planned sale of up to 30,000 shares of common stock, to be sold through Morgan Stanley Smith Barney LLC on or after 09/01/2026, following a stock option exercise. The notice also lists sales during the prior three months totaling 40,000 shares of Mirum common stock.
Mirum Pharmaceuticals, Inc. (MIRM) reported insider equity transactions by Jolanda Howe, its SVP, Global Controller. On 2026-08-18, Howe exercised 40,000 employee stock options at an exercise price of $6.27 per share, acquiring an equal number of common shares. On the same date, she sold 40,000 common shares at $100.00 per share in a transaction described as a sale in an open market or private transaction. The option grant was fully vested at the time of exercise, and the option position reported in this filing was reduced to zero.
Mirum Pharmaceuticals, Inc. (MIRM) reports that officer Jolanda Marie Howe has notified of a proposed sale of 40,000 common shares, to be sold for cash on 08/18/2026 through Morgan Stanley Smith Barney, with an aggregate market value of $4,000,000.00, following a stock option exercise. She also reported prior sales of 1,840, 2,721, and 2,594 shares of common stock in June, July, and August 2026, respectively.
Janus Henderson Group Ltd., a Jersey-organized asset management group, reports beneficial ownership in Mirum Pharmaceuticals, Inc. common stock. Through its various investment adviser subsidiaries managing client accounts referred to as Managed Portfolios, it may be deemed to beneficially own 5,909,184 shares of Mirum common stock, representing 9.7% of the class as of June 30, 2026. Janus Henderson has no sole voting or dispositive power over these shares but holds shared voting and shared dispositive power over all 5,909,184 shares. The Managed Portfolios, not Janus Henderson or its parent owners, have the right to receive all dividends and sale proceeds, and no single Managed Portfolio holds more than five percent of Mirum’s common stock.
Mirum Pharmaceuticals, Inc.'s Chief Financial Officer, Eric Bjerkholt, reported a sale of 6,001 shares of common stock on August 11, 2026 at a weighted average price of $99.90 per share, in a transaction described as a sale in the open market or a private transaction. The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on March 9, 2026. Following this transaction, Bjerkholt beneficially owns 36,355 shares of Mirum common stock, including 175 shares acquired on May 10, 2026 under the Employee Stock Purchase Plan.
Mirum Pharmaceuticals, Inc. CEO Christopher Peetz exercised an employee stock option for 20,000 shares of common stock at an exercise price of $2.936 per share and received 20,000 shares on August 10, 2026. On the same date he sold a total of 20,000 common shares in three tranches at weighted average prices of $98.51, $99.25, and $100.14 per share pursuant to a Rule 10b5-1 Plan. Following the option exercise, he reported 88,487 stock options remaining and an indirect holding of 187,500 shares held by The Peetz Family Trust.